SCHEMBL4005280

SCHEMBL4005280

COc1ccc([C@@H](Nc2ccc(CN)cc2)[C@@H](CCCOc2cccc(C(c3ccccc3)(c3ccccc3)c3ccc(F)cc3)c2)C(=O)N(C)[C@@H](C)[C@@H](O)c2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 10/20 0.40
NPY2R P49146 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CRHBP P24387 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
CRHR2 Q13324 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NR1H3 Q13133 3/20 0.35
KLK7 P49862 1/20 0.34
GAA P10253 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ADRB3 P13945 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4000734 0.85 NPY5R (0.47) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL5158316 0.85 NPY5R (0.47) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764904 0.85 NPY5R (0.47) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764898 0.84 NPY5R (0.42) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764876 0.83 NPY5R (0.46) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL4000662 0.80 NPY5R (0.41) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL3996620 0.80 NPY5R (0.38) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764899 0.79 NPY5R (0.42) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764897 0.77 NPY5R (0.39) NPY5RNPY2RMEN1KMT2ALMNA
SCHEMBL13764882 0.72 NPY5R (0.42) NPY5RNPY2RMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563888-B2 Process for the preparation of diphenyl azetidinone derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-21 US disclosed
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 US disclosed
EP-1753717-A1 METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2007-02-21 EP disclosed
WO-2005113495-A1 METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES CYP46A1, APOB, DHCR7 NPY5R 714/4885NPY2R 755/4885MEN1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.